Atossa Therapeutics Inc (NAS:ATOS)
$ 1.13 0.02 (1.8%) Market Cap: 142.11 Mil Enterprise Value: 55.63 Mil PE Ratio: 0 PB Ratio: 1.66 GF Score: 40/100

Atossa Therapeutics Inc Q2 Investor Summit Transcript

May 03, 2022 / 02:15PM GMT
Release Date Price: $0.982 (-2.77%)
Kyle Guse
Atossa Therapeutics, Inc. - CFO & General Counsel

All right. We're going to go ahead and get started. Thanks, everybody, for coming. And I'm not sure if all of the microphone turned on kind of the spar. I'm Kyle Guse, I'm the CFO and General Counsel at Atossa. I'm going to tell you how we're going to cure breast cancer.

So Atossa is a NASDAQ-listed, SEC-combined company, so please read our SEC filings before making any investment in Atossa. So we are a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need with the current focus on oncology, primarily breast cancer and infectious disease, primarily COVID-19. Also, most of time talking about the breast cancer part of our business. We're a small group, we can make this interactive, if you like. If you have questions, feel free to interrupt as we go forward here.

So first, let me give you an overview of the company. On the breast cancer side of the business, we're developing a small molecule called Endoxifen, and we're developing this in a couple of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot